Opinion|Videos|May 30, 2025
Personalized Care: How Do NSCLC Treatment Modifications and Patient-Specific Factors Impact Health Outcomes?
Author(s)Lauren Ledbetter, PharmD, BCOP
A panelist discusses how maintaining efficacy while preserving quality of life requires personalized approaches including dose adjustments or agent rotation based on specific toxicities, and how selecting the appropriate EGFR inhibitor depends on patient comorbidities, performance status, baseline conditions (such as interstitial lung disease or cardiac issues), and patient preferences.
Advertisement
Episodes in this series
Balancing Efficacy and Quality of Life
- Approaches to managing toxicity:
- Dose adjustments within recommended ranges
- Temporary holds until toxicity resolves
- Rotation to alternative agents within the same class
- EGFR tyrosine kinase inhibitor selection factors:
- Consider patient comorbidities and concomitant medications
- Baseline interstitial lung disease: may favor erlotinib over osimertinib
- Cardiac comorbidities (low ejection fraction, QTc prolongation): may favor erlotinib
- Poor performance status: minimize agents that could contribute to toxicities
- Patient preferences and lifestyle considerations significantly impact adherence
Advertisement
Related to this article
SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
On NET Cancer Day, a return visit for an over-the-counter antidiarrheal illustrates how pharmacists can identify a symptom pattern and help patients seek evaluation.
A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.
Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5